No Evidence of a Genetic Polymorphism in the Oxidative Metabolism of Midazolam
- 1 November 1988
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 15 (5) , 319-325
- https://doi.org/10.2165/00003088-198815050-00004
Abstract
The benzodiazepine midazolam is rapidly eliminated by oxidative metabolism. In young healthy volunteers elimination half-life (t½) is about 2.4 hours. A recent study showed a prolonged t½from 8 to...This publication has 21 references indexed in Scilit:
- Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.British Journal of Clinical Pharmacology, 1986
- Midazolam Pharmacodynamics and Pharmacokinetics during Acute HypovolemiaAnesthesiology, 1985
- Midazolam: pharmacology and uses.1985
- Pharmacogenetic Perspectives: Genes, Drugs and DiseaseHepatology, 1984
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Midazolam kineticsClinical Pharmacology & Therapeutics, 1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979